Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRON-RLS: Intravenous Iron in Drug-resistant Restless Legs Syndrome
NCT07822607Phase 2Not yet recruiting
- Sponsor
- CHU Montpellier
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ferric carboxymaltose in restless legs syndrome (RLS) (2 arms), sponsored by CHU Montpellier. Primary endpoint: International Restless Legs Study Group Severity Rating Scale. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT07822607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07822607.